Gal­der­ma drug pass­es PhI­II in rare skin dis­ease, set­ting the stage for ap­proval re­quest

Der­ma­tol­ogy be­he­moth Gal­der­ma is one step clos­er to reg­u­la­tors’ doorsteps for a mon­o­clon­al an­ti­body it li­censed from Chugai Phar­ma­ceu­ti­cal af­ter a Phase III read­out Wednes­day.

The for­mer Nestlé Skin Health unit said that the drug, named nemolizum­ab, passed muster in one of two Phase III tri­als in the rare skin dis­ease pruri­go nodu­laris. The drug, test­ed on its own, was able to clear most skin le­sions and re­duce itch­ing in pa­tients with the rare skin dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER